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Abstract
Purpose: Evaluate T2 weighted MRI (T2W), diffusion weighted imaging (DWI), and dynamic contrast enhanced 
MRI (DCE-MRI) for determining areas of prostate cancer recurrence to target biopsy or salvage treatment in patients 
previously treated with I-125 seed brachytherapy.
Material and methods: MRI data from 15 patients, whose primary treatment was I-125 seed brachytherapy and 
who were subsequently treated with partial gland salvage high-dose-rate brachytherapy were retrospectively ana-
lyzed. Two radiologists independently reviewed imaging on two occasions blinded to clinical and biopsy information. 
At first review, the T2W and DWI sequences were assessed for likely presence of tumor and at second review, the 
additional DCE-MRI sequence was assessed. Results were recorded and compared on a prostate diagram divided into 
12 sectors (quadrants at each of base, mid-gland, and apex) plus seminal vesicles (SV).
Results: Number of patients for whom recurrence was visible was 7/15 for T2W, 6.5/15 for DWI, and 15/15 for 
DCE-MRI (average of results for the two radiologists). Approximately, half of the sectors identified as showing recur-
rence were at the anterior base of the prostate.
Conclusions: In prostate cancer patients previously treated with I-125 permanent seed implants, DCE-MRI is supe-
rior to T2W and DWI in defining areas of recurrence, and should be used to target biopsy and for treatment planning 
of focal salvage therapies.
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Purpose
Permanent seed implant brachytherapy is a standard 
primary treatment for low- or intermediate-risk localized 
prostate cancer. A proportion of patients will experience 
recurrence and combined with the high incidence of pros-
tate cancer, this means that significant numbers of men 
with non-metastatic prostate cancer will develop bio-
chemical failure following primary radiation treatment. 
Multi-parametric magnetic resonance imaging (mp-MRI) 
has an important role in localizing areas of recurrence to 
guide targeted biopsies and planning salvage treatments. 
The ability to perform targeted partial gland salvage 
re-treatments using brachytherapy as opposed to re-treat-
ing the whole prostate gland may allow a higher dose 
to be given to the tumor, while reducing dose to organs 
at risk that have already been irradiated by the primary 
treatment [1]. The PI-RADs v2 radiology guidelines [2] for 
reporting mp-MRI before therapy recommend that diffu-
sion weighted imaging (DWI) is the primary determin-
ing sequence in the peripheral zone of the prostate and 
that T2 weighted MRI (T2W) is the primary determining 
sequence in the transition zone of the prostate, while dy-
namic contrast enhanced MRI (DCE-MRI) has only a mi-
nor role. However, after radiotherapy, radiation induced 
fibrosis may make T2W and DWI less useful. DCE-MRI 
demonstrates cancer induced neo-angiogenesis and may 
be of more value [3,4]. In addition, for patients previously 
treated with seed implant brachytherapy, the seeds may 
create artifact that further reduces the value of DWI.
This study of patients previously treated with seed 
implant brachytherapy compares T2W, DWI and DCE-
MRI in terms of their usefulness for localizing areas of 
prostate cancer recurrence.
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Material and methods
Fifteen patients who had been treated with I-125 seed 
implant monotherapy (145 Gy minimum peripheral dose) 
between 2002 and 2013, and were subsequently treated 
with partial gland salvage high-dose-rate (HDR) prostate 
brachytherapy between 2010 and 2018 were retrospective-
ly assessed. These patients were classified as low- or in-
termediate-risk at original diagnosis. The mean time from 
primary treatment to salvage treatment was 8 years (range, 
4-14 years). At the time of the salvage treatment, the aver-
age age was 70 (range, 63-78 years). Mean prostate-spe-
cific antigen was 11 (range, 3-20) at initial treatment and 
5 (range, 1-9) at relapse. All patients were treated with 
a single 19 Gy fraction of focal salvage HDR brachyther-
apy, with the focal target determined using mp-MRI data 
and biopsy results. Targeted trans-rectal ultrasound tem-
plate biopsy was performed after mp-MRI and consisted 
of systematic sampling with additional samples taken 
from areas suspicious for recurrence in the mp-MRI.
The mp-MRI acquisition was performed 2-6 months 
before salvage treatment and consisted of T2W, DWI, 
and DCE-MRI. Scans were performed on Avanto or Aera 
(Siemens AG, Munich, Germany) 1.5T scanners, using 
phased-array pelvic and spine coils for signal reception. 
T2W MRI used a turbo-spin echo (SE) sequence with rep-
etition time (TR) 3200 ms, echo time (TE) 87 ms, echo train 
length 13, 0.6 mm pixel size, slice thickness 3 mm. DWI 
MRI used a single shot SE-echo planar imaging (EPI) se-
quence with TR 3000 ms, TE 81 ms, 1.5 mm pixel size, 
slice thickness 4 mm, b-values 0, 150, 1000 s/mm2. Raw 
DWI images as well as the apparent diffusion coefficient 
(ADC) maps generated by the scanner (using all three 
b-values) were reviewed for this study. Some data sets 
also had calculated b = 1400 s/mm2 images. DCE MRI 
used a 3D spoiled gradient echo sequence with TR 4.5 ms, 
TE 1.6 ms, flip angle 15°, 1.4 × 1.4 × 3 mm pixel size, 30 ac-
quisitions with 10s-time resolution, and a bolus injection 
of 0.1 mmol/kg Dotarem® (Guerbet Group, Villepinte, 
France). Raw DCE images were reviewed for areas of ear-
ly enhancement.
MRI images were reviewed on two occasions by two 
radiologists with over 20 years and 5-year experience of 
prostate MRI, respectively. At the first review, the T2W 
and DWI sequences were assessed for likely presence 
of tumor and at the second review, undertaken at least 
2 weeks later, the additional DCE sequence was assessed. 
DCE sequences were assessed blinded to the T2W/DWI 
sequences to reduce recall bias and as the DCE-MRI imag-
es showed sufficient anatomical detail to allow the prostate 
to be clearly visualized (Figure 1). Each review was per-
formed independently by the two consultant radiologists, 
blinded to clinical and biopsy information. Results were re-
corded and compared on a prostate diagram divided into 
12 sectors (quadrants at each of base, mid-gland and apex) 
plus seminal vesicles (SV). Each sector was scored as either 
positive or negative for suspicion of recurrence. After this 
analysis was complete, the biopsy reports for each patient 
were checked to ensure that sectors identified as positive 
or negative were consistent with the biopsy results. 
Results
The first radiologist found recurrence visible in 6/15 
patients for T2W, 5/15 for DWI, and 15/15 for DCE-MRI. 
The second radiologist found recurrence visible in 8/15 
patients for T2W, 8/15 for DWI, and 15/15 for DCE-MRI. 
For the 3 patients in which recurrence was scored differ-
ently by the two radiologists, the area of recurrence iden-
tified was smaller for T2W/DWI compared to DCE-MRI. 
For two of the patients where recurrence was visible on 
DWI, the DWI visible recurrence was confined to the SV 
where there are no seeds present. 
From the sector-based analysis, two patients had SV 
only recurrence. For the remaining 13 patients, the recur-
rence involved a median of 2/12 prostate sectors (range, 
1/12-5/12) predominantly in anterior base sectors; Figu-
re 2 shows the total number of recurrences detected in 
each sector. The total number of involved sectors was 
34 and 44 for the first and second radiologist, respective-
ly. Per patient, the median number of sectors scored dif-
ferently was 2 (range, 0-5). These differences were subse-
quently reviewed, and, in all cases, the two radiologists 
agreed on at least one sector, indicating that the differ-
ences were down to the extent of the recurrence (whether 
or not to include adjacent sectors). Following the imaging 
review, targeted biopsy results were reviewed, and, in all 
cases, the areas identified as positive or negative for re-
currence were consistent with the biopsy results (as this 
was a retrospective imaging study it was only possible to 
verify the recurrence location in terms of gross anatomi-
cal location rather than verify each sector individually). 
Fig. 1. Mp-MRI images for a patient whose original treatment was I-125 seeds, anterior tumor is visible as increased enhance-
ment on DCE-MRI. In the DWI ADC map there are possible darker areas of restricted diffusion, but artifacts generated by the 
implanted seeds make this image hard to interpret. The tumor is not visible on the T2W images. Targeted biopsy confirmed 
presence of tumor in anterior cores only
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Discussion
This study has compared T2W, DWI, and DCE-MRI for 
localizing areas of prostate cancer recurrence in patients 
previously treated with I-125 seed implant brachythera-
py. The usefulness of DCE-MRI in assessing recurrence in 
prostate cancer patients treated with external beam radio-
therapy has been assessed before [5,6,7] but this study is 
the first to focus purely on patients with I-125 seed implant 
for their primary treatment, and specifically for the pur-
pose of planning focal salvage brachytherapy treatments. 
A study by Donati et al. [7] did include some seed implant 
patients and concluded that DCE-MRI was helpful in these 
cases, although not adding value for patients treated with 
external beam radiotherapy. That study also focused pri-
marily on imaging for detecting recurrence rather than for 
planning treatments. Mp-MRI has a crucial role both in 
guiding targeted biopsy and in defining the area for focal 
treatment, allowing dose escalation to the area of recur-
rence, whilst minimizing dose to organs at risk.
In this study, DCE-MRI could be used to visualize the 
area of recurrence in all 15 patients, whereas T2W and 
DWI were only useful in approximately half of patients. 
The poorer performance of DWI in seed implant patients 
is due to artifact generated by the seeds in addition to 
the effects of the original treatment. Two radiologists 
reviewed images for this study and their results were 
reasonably consistent, although differences in their eval-
uation of the extent of the tumor could translate to differ-
ences in volumes targeted for focal salvage treatments. 
This points to a limitation of DCE-MRI in that regions 
of enhancement are not generally very clearly defined. 
A further limitation of this study is that DCE-MRI can 
show abnormal enhancement due to benign prostatic 
hyperplasia or inflammation, and this could have caused 
some of the areas of recurrence to be overestimated. How-
ever, in planning focal salvage treatments it is preferable 
to treat all areas suspicious for recurrence. Recurrences 
were much more commonly seen at the anterior base and 
this is consistent with studies that show this area of the 
prostate tends to receive lower dose [8,9].
Conclusions
In prostate cancer patients previously treated with 
I-125 permanent seed implants, DCE-MRI is superior to 
T2W and DWI in defining areas of recurrence, and should 
be used to target biopsy and for treatment planning of 
focal salvage therapies.
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Fig. 2. The number of times each sector was identified as involved for the 15 I-125 seed patients. The numbers given are the 
average values for the two radiologists who reviewed the images. Four patients also had recurrence in the seminal vesicles
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